Conexiant’s news site is now MDSpire News. Learn more
Advertisement
NASPGHAN Position Paper Outlines Therapeutic Drug Monitoring Targets for Pediatric IBD
A NASPGHAN position paper co-authored by Ashish S. Patel, MD, of Phoenix Children’s outlines therapeutic drug monitoring targets for biologics in pediatric IBD. See the infliximab trough targets and when to call a specialist.
The article summarizes NASPGHAN guidance on therapeutic drug monitoring and biologic drug-level targets for children with inflammatory bowel disease.
Approach:
Monitoring strategy: The position paper describes proactive TDM, which checks drug levels before problems arise, and reactive TDM, which checks levels after a problem appears.
Infliximab targets: The paper recommends trough levels above 18 micrograms per milliliter at week 6 and above 7 micrograms per milliliter at week 14, followed by proactive monitoring every 6 to 12 months during maintenance.
Other biologics and patient groups: The paper includes targets for biologics by disease type. It notes that children with perianal fistulas may need higher levels, and children diagnosed before age 6 may clear drugs faster and require more intensive dosing and close monitoring.
Key Findings:
Children with IBD have fewer medication options than adults, and the paper presents TDM as a way to optimize available biologic therapies.
For anti-TNF therapy, monitoring includes drug levels and antibodies; for newer biologics, the focus is on drug levels, with less concern about antibody formation.
The paper recommends proactive infliximab monitoring during maintenance.
Interpretation:
Ashish S. Patel, MD, co-author of the paper, said limited medication availability in pediatric IBD makes therapeutic drug monitoring important for optimizing and managing available therapies. He said that when monitoring begins only after a problem appears, it is often too late to make changes that keep a child on the same therapy.
Limitations:
The supplied article context does not provide the full drug-by-disease target table or detailed evidence grading.
The supplied context gives specific numeric targets only for infliximab.
Conclusion:
The position paper provides pediatric IBD clinicians with drug-level targets and monitoring guidance for biologic therapy.